From the *Henry Low Heart Center, Department of Cardiology, Hartford Hospital, Hartford, Connecticut; and †Department of Sports Medicine, Children's Hospital, Boston, Massachusetts.
Submitted for publication July 29, 2010; accepted January 6, 2011.
Dr Paul Thompson is a consultant for AstraZeneca International, Merck & Co, Inc, Schering-Plough Corporation, Takeda Pharmaceutical Company Limited, Roche, and Genomas, Inc, and is a member of the speaker's bureau for Merck & Co, Inc, Pfizer Inc, Abbot Laboratories, AstraZeneca International, and Schering-Plough Corporation.
The authors report no conflicts of interest.
Corresponding Author: Beth Parker, PhD, Henry Low Heart Center, Hartford Hospital, Hartford, CT 06102 (e-mail: [email protected]).